# **Data Changes for the CCDD MARCH Release Candidate 2024**

## **Based on the QA Release Generation** 2024-03-01

|  |  |
| --- | --- |
| Data entered by | A.Raghuveer |
| Data checked by | M.Taylor |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] |  |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
| 8002418 | cilgavimab and tixagevimab |

## **NTP File**

### **Deprecation**

The following NTP concept(s) needs to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – Inactive**

The following NTP concept(s) are generating as Active but need to be set to **inactive** to align with their respective MPs.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
|  | [NONE] |  | Inactive |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9014675 | cilgavimab 150 mg per 1.5 mL solution for injection vial with tixagevimab 150 mg per 1.5 mL solution for injection vial |
| 9004463 | coal tar 1 % shampoo |
| 9013541 | collagenase clostridium histolyticum 250 unit per g cutaneous ointment |
| 9014735 | desmopressin (desmopressin acetate) 25 mcg sublingual tablet |
| 9005078 | palonosetron (palonosetron hydrochloride) 0.5 mg oral capsule |
| 9012872 | vilazodone hydrochloride 10 mg oral tablet with vilazodone hydrochloride 20 mg oral tablet |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. The product has been transferred from DPD to LNHPD.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
|  | [NONE] |  | Deprec |

### **Status update – deprecation**

The following MP concepts are generating as active but need to be set to **deprecated**. Some of these products have been assigned a new DIN, others have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Deprec |

### **Status update – Inactive**

The following MP concepts are generating as active but need to be set to **inactivated**. The DIN is still active but these particular presentations have been discontinued.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
|  | [NONE] | Inactive |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Inclusion list to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 86758 | 2381729 | ALOXI (palonosetron (palonosetron hydrochloride) 0.5 mg oral capsule) KNIGHT THERAPEUTICS INC. | Dormant |
| 61179 | 2237820 | AMERGE (naratriptan (naratriptan hydrochloride) 1 mg oral tablet) GLAXOSMITHKLINE INC | Cancelled post-market Expiry 2024.02.17 |
| 61180 | 2237821 | AMERGE (naratriptan (naratriptan hydrochloride) 2.5 mg oral tablet) GLAXOSMITHKLINE INC | Cancelled post-market Expiry 2024.02.17 |
| 100777 | 2518457 | ANTI-DANDRUFF SHAMPOO (pyrithione zinc 1 % shampoo) FIRST AID BEAUTY LTD | Cancelled post-market Expiry 2022.05.01 |
| 95684 | 2468417 | CHILDREN'S ACETAMINOPHEN DYE-FREE (acetaminophen 160 mg per 5 mL oral suspension) PERRIGO INTERNATIONAL | Cancelled post-market Expiry 2024.02.29 |
| 101539 | 2526271 | EVUSHELD (cilgavimab 150 mg per 1.5 mL solution for injection vial with tixagevimab 150 mg per 1.5 mL solution for injection vial) ASTRAZENECA CANADA INC | Dormant |
| 17954 | 2131056 | LIORESAL INTRATHECAL 0.5MG/ML (baclofen 10 mg per 20 mL solution for injection ampoule) NOVARTIS PHARMACEUTICALS CANADA INC | Cancelled post-market Expiry 2024.02.29 |
| 17276 | 2131064 | LIORESAL INTRATHECAL 2MG/ML (baclofen 10 mg per 5 mL solution for injection ampoule) NOVARTIS PHARMACEUTICALS CANADA INC | Cancelled post-market Expiry 2024.02.29 |
| 88288 | 2397927 | NOCDURNA (desmopressin (desmopressin acetate) 25 mcg sublingual tablet) FERRING INC | Cancelled post-market Expiry 2024.02.29 |
| NA | 77700956 | PROPOFOL (propofol 1000 mg per 100 mL emulsion for injection vial) BAXTER CORPORATION | Cancelled post-market Expiry 2022.06.30 |
| NA | 77700954 | PROPOFOL (propofol 200 mg per 20 mL emulsion for injection vial) BAXTER CORPORATION | Cancelled post-market Expiry 2022.06.30 |
| NA | 77700955 | PROPOFOL (propofol 500 mg per 50 mL emulsion for injection vial) BAXTER CORPORATION | Cancelled post-market Expiry 2022.06.30 |
| 16678 | 2063670 | SANTYL (collagenase clostridium histolyticum 250 unit per g cutaneous ointment) SMITH & NEPHEW INC | Dormant |
| 79280 | 2307146 | T/GEL THERAPEUTIC SHAMPOO EXTRA STRENGTH (coal tar 1 % shampoo) JOHNSON & JOHNSON INC | Cancelled post-market Expiry 2024.02.29 |
| 68470 | 2244494 | TEVA-LEVOCARBIDOPA (carbidopa 10 mg and levodopa 100 mg oral tablet) TEVA CANADA LIMITED | Dormant |
| 92850 | 2443759 | VIIBRYD (vilazodone hydrochloride 10 mg oral tablet with vilazodone hydrochloride 20 mg oral tablet) ABBVIE CORPORATION | Cancelled post-market Expiry 2024.02.29 |
| 98507 | 2495112 | ZERO FRESH BREATH (cetylpyridinium chloride 0.075 % mouthwash) COLGATE-PALMOLIVE CANADA INC | Cancelled post-market Expiry 2022.11.30 |

## **Exclusion List (on GitHub)**

The following changes have been made to the Exclusion List for the FEBRUARY 2024 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Exclusion List are as follows:  
ACTION is either:

* STAY on Exclusion List
* ADD to Exclusion List
* REMOVE from Exclusion List

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
| 63c8f110ed79d2e861bae01cb8891ce7 | cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection | 100489 | 02515490 | VYXEOS (cytarabine 100 mg and daunorubicin 44 mg powder for solution for injection) JAZZ PHARMACEUTICALS IRELAND LIMITED | STAY |
| 9000965 | ketorolac tromethamine 30 mg per mL solution for injection | 101242 | 2523310 | KETOROLAC TROMETHAMINE INJECTION USP (ketorolac tromethamine 30 mg per mL solution for injection) JAMP PHARMA CORPORATION | REMOVE |
| 9014308 | filgrastim 300 mcg per 0.5 mL solution for injection | 101023 | 2520990 | NYPOZI (filgrastim 300 mcg per 0.5 mL solution for injection) TANVEX BIOPHARMA USA, INC. | REMOVE |
| 9014309 | filgrastim 480 mcg per 0.8 mL solution for injection | 101024 | 2521008 | NYPOZI (filgrastim 480 mcg per 0.8 mL solution for injection) TANVEX BIOPHARMA USA, INC. | REMOVE |
| 9e3fb80210482640e5444ef81ae1c6a9 | cisplatin 1 mg per mL solution for injection | 102507 | 2536285 | CISPLATIN INJECTION BP (cisplatin 1 mg per mL solution for injection) HIKMA CANADA LIMITED | ADD |
| 5337a590b31d246add65ba99b6d94f12 | elranatamab 44 mg per 1.1 mL solution for injection | 103201 | 2543559 | ELREXFIO (elranatamab 44 mg per 1.1 mL solution for injection) PFIZER CANADA ULC | ADD |
| 41d14fe928628e909f59b06c220a4842 | elranatamab 76 mg per 1.9 mL solution for injection | 103202 | 2543567 | ELREXFIO (elranatamab 76 mg per 1.9 mL solution for injection) PFIZER CANADA ULC | ADD |
| 9cda20aefa820edec57ea9744c742ecf | ranibizumab 10 mg per mL solution for injection | 103083 | 2542250 | RANOPTO (ranibizumab 10 mg per mL solution for injection) TEVA CANADA LIMITED | ADD |
| 9014932 | rocuronium bromide 10 mg per mL solution for injection | 101907 | 2529831 | ROCURONIUM BROMIDE INJECTION (rocuronium bromide 10 mg per mL solution for injection) JAMP PHARMA CORPORATION | ADD |